Korenblik, R. http://orcid.org/0000-0002-6356-3076
Olij, B.
Aldrighetti, L. A.
Hilal, M. Abu
Ahle, M.
Arslan, B.
van Baardewijk, L. J.
Baclija, I.
Bent, C.
Bertrand, C. L.
Björnsson, B.
de Boer, M. T.
de Boer, S. W.
Bokkers, R. P. H.
Rinkes, I. H. M. Borel
Breitenstein, S.
Bruijnen, R. C. G.
Bruners, P.
Büchler, M. W.
Camacho, J. C.
Cappelli, A.
Carling, U.
Chan, B. K. Y.
Chang, D. H.
choi, J.
Font, J. Codina
Crawford, M.
Croagh, D.
Cugat, E.
Davis, R.
De Boo, D. W.
De Cobelli, F.
De Wispelaere, J. F.
van Delden, O. M.
Delle, M.
Detry, O.
Díaz-Nieto, R.
Dili, A.
Erdmann, J. I.
Fisher, O.
Fondevila, C.
Fretland, Å.
Borobia, F. Garcia
Gelabert, A.
Gérard, L.
Giuliante, F.
Gobardhan, P. D.
Gómez, F.
Grünberger, T.
Grünhagen, D. J.
Guitart, J.
Hagendoorn, J.
Heil, J.
Heise, D.
Herrero, E.
Hess, G. F.
Hoffmann, M. H.
Iezzi, R.
Imani, F.
Nguyen, J.
Jovine, E.
Kalff, J. C.
Kazemier, G.
Kingham, T. P.
Kleeff, J.
Kollmar, O.
Leclercq, W. K. G.
Ben, S. Lopez
Lucidi, V.
MacDonald, A.
Madoff, D. C.
Manekeller, S.
Martel, G.
Mehrabi, A.
Mehrzad, H.
Meijerink, M. R.
Menon, K.
Metrakos, P.
Meyer, C.
Moelker, A.
Modi, S.
Montanari, N.
Navines, J.
Neumann, U. P.
Peddu, P.
Primrose, J. N.
Qu, X.
Raptis, D.
Ratti, F.
Ridouani, F.
Rogan, C.
Ronellenfitsch, U.
Ryan, S.
Sallemi, C.
Moragues, J. Sampere
Sandström, P.
Sarriá, L.
Schnitzbauer, A.
Serenari, M.
Serrablo, A.
Smits, M. L. J.
Sparrelid, E.
Spüntrup, E.
Stavrou, G. A.
Sutcliffe, R. P.
Tancredi, I.
Tasse, J. C.
Udupa, V.
Valenti, D.
Fundora, Y.
Vogl, T. J.
Wang, X.
White, S. A.
Wohlgemuth, W. A.
Yu, D.
Zijlstra, I. A. J.
Binkert, C. A.
Bemelmans, M. H. A.
van der Leij, C.
Schadde, E.
van Dam, R. M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
https://doi.org/10.1007/s00270-022-03176-1
Documents that mention this clinical trial
Funding for this research was provided by:
KWF Kankerbestrijding (12501)
Maastricht Universitair Medisch Centrum
Abbott Vascular
Guerbet
National Institute for Health Research (274587)
Article History
Received: 29 November 2021
Accepted: 8 May 2022
First Online: 5 July 2022
Declarations
:
: The authors declare that they have no conflict of interest.
: All procedures performed in the DRAGON 1 trial are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participating centers obtained ethical and local approval by the board of directors (if applicable). For the sponsor site, Maastricht, the METC azM/UM approved this trial (NL7135.068.19 /METC19-078).
: Informed consent will be obtained from all individual participants included in the study according to Good Clinical Practice guidelines.
: For this type of study, study protocol paper, consent for publication is not required.